论文部分内容阅读
似乎还没有哪个企业像归真堂这样,在IPO的过程中饱受关注和非议。国内各大媒体、众多社会名人以及动物保护组织等悉数卷入其中,就归真堂的“活熊取胆”模式和上市问题,展开了激烈的争论。在此之前,归真堂作为一家民营小药企可谓名不见经传,很多人连听说都没听说过。按照归真堂及其支持者的说法,给熊造瘘取胆,熊并不痛苦,而且还“很舒服”;而反对者称这是对动物的残忍虐待,有悖人道。关键是还有可替代性的中药
There does not seem to be any enterprise that has been treated like a real one and has received much attention and criticism in the IPO process. The major domestic media, many social celebrities, and animal protection organizations have all been involved, and there has been fierce debate over the “live bear bile” model and listing issues that have been attributed to Zhenzhen. Prior to this, Guizhentang was not known as a private drug company, and many people did not even hear about it. According to Guizhengtang and his supporters, bears were taken for courage and bears were not painful, and they were still “very comfortable”; opponents called it a cruel treatment of animals, and were inhumane. The key is that there are alternative Chinese medicines